Vobramitamab Biosimilar, also known as Anti-CD276 mAb, is a monoclonal antibody that targets the protein CD276, which is overexpressed in various types of cancer cells. This biosimilar is a research-grade version of the original Vobramitamab antibody, and is used in laboratory and preclinical studies for the development of potential cancer therapies. In this article, we will explore the structure, activity, and potential applications of Vobramitamab Biosimilar.
Vobramitamab Biosimilar is a recombinant humanized monoclonal antibody, meaning that it is produced through genetic engineering techniques to resemble human antibodies. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable regions are responsible for binding to the target protein CD276, while the constant regions determine the functional properties of the antibody.
Vobramitamab Biosimilar specifically targets the protein CD276, also known as B7-H3, which is a member of the B7 family of immune checkpoint proteins. CD276 is overexpressed in many types of cancer cells, including breast, lung, and prostate cancer, and has been shown to play a role in tumor growth and immune evasion. By binding to CD276, Vobramitamab Biosimilar can potentially block its activity and inhibit tumor growth.
In addition to its direct anti-tumor activity, Vobramitamab Biosimilar has also been shown to enhance the immune response against cancer cells. This is due to its ability to bind to CD276 on immune cells, such as T cells and natural killer cells, and activate them to attack cancer cells. This dual mechanism of action makes Vobramitamab Biosimilar a promising candidate for cancer immunotherapy.
As a research-grade antibody, Vobramitamab Biosimilar is primarily used in laboratory and preclinical studies to investigate its potential as a therapeutic agent for cancer. It is often used in combination with other anti- cancer drugs or as part of immunotherapy strategies to assess its efficacy and safety.
In addition to its use in research, Vobramitamab Biosimilar has also been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of neuroblastoma, a type of childhood cancer. This designation is given to drugs that show promise in treating rare diseases, and provides incentives for their development and approval.
In summary, Vobramitamab Biosimilar, also known as Anti-CD276 mAb, is a research-grade monoclonal antibody that targets the protein CD276, which is overexpressed in various types of cancer cells. It has a unique dual mechanism of action, both directly inhibiting tumor growth and enhancing the immune response against cancer cells. Its potential as a cancer therapy is currently being investigated in laboratory and preclinical studies, and it has been granted orphan drug designation for the treatment of neuroblastoma. With further research and development, Vobramitamab Biosimilar may prove to be a valuable addition to the arsenal of anti- cancer therapies.
There are no reviews yet.